Outlook: British Biotech
Tuesday 16 February 1999
First there was the grand dream of creating a "New Glaxo", a whizzy pharmaceutical giant based on some unproven compounds. Then came the bitter tussle with Andrew Millar, its former chief scientist, who was sacked for examining clinical data on the company's leading products and blowing the whistle on overoptimistic statements. The corker of a row triggered two investigations by stock exchange authorities, a Parliamentary enquiry and a collapse in the share price. The faces around the boardroom table changed since then but the results have remained the same, witness yesterday's trial failure, which at least partially vindicates Dr Millar's actions.
The new men in charge claim that Marimastat can still work on other cancers and that there are nine other studies to prove it. Shareholders should be patient, they say, these are early days, give us another year. But this is asking a lot of investors who have seen the value of their shares plunge by almost 93 per cent over the past five years. After yesterday's events, there must be a serious question over the future of British Biotech.
The company has a strong balance sheet with cash of over pounds 100m. And it is only a couple of years since this company was the rising star in Britain's rapidly growing biotech sector. But given the dreadful track record and uncertain prospects perhaps the board should finally admit defeat.Would it not now be the honourable course to return the cash to the long-suffering investors and draw the curtains on this sorry tale?
Times are so tough in Italy that Mafiosi are considering getting jobs
The man they forgot to lock up: Mike Anderson was sentenced to 13 years in jail, but the police never came
Unbeliebable: The White House offers 'no comment' to anti-Justin Bieber petition
Loch Ness Monster found on Apple Maps?
South Korea ferry disaster: Families watch as remains of Sewol victims returned to shore
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
'Sinful': Video of British Muslims dancing to Pharrell Williams's hit Happy comes under attack
An open letter to Nigel Farage: you may smile, but I am not seduced
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
Abdullah Deghayes: My son was the martyr of a just cause, says father of British teenager killed in Syria conflict
- 1 Disabled people are trapped in assessment 'nightmare' by PIP benefits regime, says Dr Stephen Duckworth
- 2 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 3 Queen turns 88: David Bailey captures another side of the Queen in birthday portrait
- 4 Loch Ness Monster found on Apple Maps?
- 5 Criminals ‘using unmanned drones and infrared cameras to find illegal cannabis farms’ – and then steal from the growers
iJobs Money & Business
Negotiable: Harrington Starr: Database Team Lead ( Leadership, Sybase, Compute...
£40000 - £50000 per annum + Bonus+Benefits+Package: Harrington Starr: C#.NET D...
£25000 - £35000 per annum + Bonus+Benefits+Package: Harrington Starr: VB.NET S...
£45000 - £55000 per annum + Bonus and Benefits: Harrington Starr: Trade Suppor...